Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination

摘要: In late 2009 transplant organizations recommended that kidney recipients be vaccinated for pandemic H1N1 influenza (pH1N1); however, the vaccine efficacy was unknown. We had offered a monovalent non-adjuvanted pH1N1 to recipients. Here we compared pre- and post-vaccination seroresponses of 151 71 hemodialysis patients 30 healthy controls. Baseline seroprotection similar between groups but significantly different at 1 month (44, 56, 87%, respectively). Seroconversion less common (32%) than dialysis (45%) controls (77%). After adjusting age gender, were more likely (2.7-fold) achieve new The likelihood in reduced by mycophenolate use (adjusted odds ratio 0.24), dose-dependent manner, eGFR 0.16 worst best). Seroprotection geometric mean antibody titers increased substantially 49 who subsequently received 2010 seasonal vaccine. Thus, requiring renal replacement therapy vaccination with Transplant recipient responses further if they receiving or lower graft function.